Writing about the new blood test in the American Journal of Respiratory and Critical Care Medicine, the researchers describe it as a measure of inflammatory gene expression.
They hope that the test can improve patient care, and help clear a backlog of promising medications now hung up in clinical trials.
"The currently accepted test, a measure of a patients' ability to exhale air, has several limitations that make it ineffective for some patients and not sensitive enough for clinical trials of many new medications," said Dr. Milene Saavedra, lead author of the study and Assistant Professor of Medicine at National Jewish Health.
"By measuring the activity of genes associated with the immune/inflammatory response, we can get a more accurate picture of the biological processes occurring inside the lungs," the researcher added.
Currently, response to medication is measured by how much air a person can rapidly exhale: forced expiratory volume in one second (FEV1).
Patients' FEV1 generally improves when inflammation is reduced, but not all patients' FEV1 improves significantly, and changes can take weeks to months to show up.
The researchers say that they have identified three genes that most accurately correlated with a positive therapeutic response, namely CD36, CD64, and ADAM9.
While CD36 and CD64 are genes associated with cells' absorption of foreign organisms and cellular debris, according to them, ADAM9 is associated with tissue destruction that allows inflammatory cells to move through tissue.
"The expression of these genes correlated with FEV1, other inflammatory markers, and various clinical factors," said co-author Dr. Jerry Nick , Associate Professor of Medicine at National Jewish.
"When combined with FEV1, they offered a more accurate and sensitive measure of response to therapy than either alone. We believe they could be extremely useful in clinical care of patients and trials of new CF therapies," Dr. Nick added.
The researchers are now conducting a trial of 60 CF patients to provide stronger statistical evidence for the power of CD36, CD64 and ADAM9 to diagnose a positive response to therapy by CF patients.